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Poster Session I 99Significance: High-dose chemotherapy with autologous stem
cell transplantation (HDC-AuSCT) has become an established pro-
cedure for treatment of multiple myeloma (MM). During HDC-
AuSCT, patients develop a symptom burden that substantially
interferes with daily activities. Theoretical Framework: Symptom
burden is the combined impact of all symptoms on one’s ability to
function as one did before onset of disease and therapy. Problem
and Purpose: Minimizing the symptom burden of HDC-AuSCT
may allow more patients the chance to receive its demonstrated ben-
efits. The purpose of this research was to explore the ability of larger
numbers of CD341 cells to decrease symptom severity during
HDC-AuSCT in patients with MM. Methods: This was a retro-
spective analysis of 17 patients with MM who completed the M.
D. Anderson Symptom Inventory (MDASI) (0–10 measurement
scale) at 6 time points from baseline to 30 days post-HDC-AuSCT.
Four patients received high doses of stem cells (9.5–15  106
CD341 cells/kg) and 13 received standard doses (4–6  106
CD341 cells/kg). Area under the curve (AUC) methodology was
used to describe the severity of the 5 most severe symptoms (fatigue,
lack of appetite, difficulty sleeping, nausea, and pain) that these pa-
tients experienced during the peritransplantation period. Results:
Means and standard deviations of symptom severity measures are
in Table 1. The mean symptom severity of the 2 groups showed
no difference at baseline. The difference in mean daily AUC be-
tween the 2 groups from cell infusion to 30 days post-HDC-AuSCT
approached significance and, more importantly, showed a large ef-
fect size of 1.2 times the common group standard deviation. The
mean symptom severity of the 5 most severe symptoms was signif-
icantly lower at nadir for the group receiving the high cell dose. Im-
plications: The mean symptom severity for the 2 groups began to
diverge sharply after cell infusion. The severity for patients receiv-
ing the larger cell dose declined immediately, whereas the severity
for patients receiving the standard cell dose rose further before de-
clining. The use of larger cell doses to decrease symptoms warrants
prospective testing in a randomized controlled trial. The mecha-
nism behind the ability of larger doses of stem cells to ameliorate
symptom severity is unclear. The known relationship between
symptom development and severity and inflammatory cytokines
(e.g., IL-6) suggests a possible cytokine-based mechanism, which
also should be explored.
Table 1. Symptom Severity during Autologous Stem Cell
Transplantation for Multiple Myeloma
Larger Cell Standard
Dose Cell DoseMeasure Mean SD Mean SD
P Value
(2-Tailed)Severity at baseline
of 5 most severe
symptoms1.35 1.06 1.86 1.71 0.49Severity at nadir
of 5 most severe
symptoms2.55 1.68 6.06 2.26 \0.012Daily AUC of 5 most
severe symptoms63.55 42.02 122.95 51.24 0.053SD 5 standard deviation.268
UPDATE ON FUNGAL INFECTIONS IN PEDIATRIC BONE MARROW
TRANSPLANT PATIENTS AT THE MATTEL CHILDREN’S HOSPITAL AT
UCLA FROM 1991–2006
Simms-Waldrip, T.R., Rosen, G.P., Kempert, P.H., Nielsen, K.,
Moore, T.B. DavidGeffen School ofMedicine at UCLA, Los Angeles, CA.
Objectives:To identify changes in fungal organisms and charac-
teristics of their infections over time in pediatric bone marrow
transplant (BMT) patients. Identify differences in fungal species
causing infections in different BMT patients. Methods: We per-
formed a retrospective cohort study of all 324 patients on the pedi-atric hematology and oncology service at UCLA between 1991 and
2006 who underwent bone marrow transplantation. Cultures posi-
tive for fungus were identified from both the microbiology lab da-
tabase as well as medical record review to identify eighty-three
unique infections in fifty-four transplant patients. Results: The
overall incidence of fungal infections in BMT recipients was
16.7%. The predominant organisms included: Candida species
(55%) and Apergillus species (21%), with Candida albicans account-
ing for 19% of all fungal species. A variety of other fungal species
comprised the remainder of infections. The distribution of organ-
isms over time demonstrated a strong trend towards an increase
in rare molds in more recent years. The respiratory tract was the
main site of infection (41%) with urine (17%) and blood (11%)
also noted as significant sites. Upon stratification of the BMT pa-
tients who developed fungal infections, the primary diagnoses
were ALL (48%) and myeloid malignancy (35%); underlying diag-
nosis, however, had little impact on the development of a fungal in-
fection in BMT patients. Of all deaths in the studied population,
fungal-related mortality of patients analyzed was 44%. Conclu-
sions: Bone marrow transplant patients have a high risk of fungal
infections, likely secondary to their severe and prolonged neutrope-
nia. This risk appears to be increasing over time with rarer organ-
isms becoming more prevalent. This emphasizes the need for the
development and implementation of improved diagnostic and ther-
apeutic strategies in order to improve survival in this population.269
A PHASE II OPEN LABEL PILOT TRIAL OF EMPIRIC DAPTOMYCIN TREAT-
MENT FOR HEMATOLOGY-ONCOLOGY PATIENTS WITH FEBRILE NEU-
TROPENIA (FN)
Bubalo, J.S.1, Ciszewski, A.O.1, Kovascovics, T.J.1, Meyers, G.1,
Mauro, M.1, Epner, E.1, Jones, N.1, Hayes-Lattin, B.1,
Deninger, M.1, Curtin, P.T.2, Leis, J.F.2, Maziarz, R.T.1 1Oregon
Health and Sciences University Hospital, Portland, OR; 2University of
California San Diego, San Diego, CA; 3Mayo Clinic, Phoenix, AZ.
FN warrants prompt attention and treatment due to potential for
associated morbidity and mortality. Broad spectrum antibiotics are
guided by putative causative organisms. Initially gram-negative and
then gram positive organisms have emerged as infectious culprits.
Therefore vancomycin is often added in FN patients still febrile af-
ter 72 hours of initial antibiotic therapy. Emerging antibiotic resis-
tance by gram-positive organisms and the bacteriostatic nature of
vancomycin, make the study of new gram-positive therapies like
the novel bactericidal, antibiotic daptomycin, critical. This pilot
study aims to determine initial efficacy, safety, and pharmacokinet-
ics (PK), of daptomycin substituted for vancomycin in FN patients.
FN patients, without pneumonia, were enrolled and received dapto-
mycin per the current IDSA FN guidelines. Patients received 6 mg/
kg as a 30 minute intravenous infusion every 24 hours. Blood sam-
ples for measurement of plasma daptomycin concentrations were
collected for PK analysis. Twenty-eight patients, 19 men/9 women,
age range 24–74 years old (median 53) have been treated. Their
weights ranged from 56.2–137 kg (median of 89.9 kg). The patient’s
had the following malignancies: 10 AML, 6 ALL, 2 multiple mye-
loma, 2 Hodgkin’s disease, 2 non-Hodgkin’s lymphoma, 1 APL,
and 1 germ cell tumor. Ten patients were post autologous and 5
post allogeneic transplants, with 13 receiving non-transplant che-
motherapy. The median and mean time to reach an afebrile state
was 4 days. Mean duration receiving daptomycin was 11 days (me-
dian 8, range 3–40 days). Infectious organisms, identified for 16/28
patients, included: coagulase-negative S. aureus, alpha-hemolytic
streptococcus, S. mitis, S. oralis, P. aeruginosa, K. pneumonia, Co-
rynebacterium, and E. coli. One patient developed a drug rash
which abated after the cessation of daptomycin, and 1 experienced
mental status changes considered possibly related to taking dapto-
mycin. One patient stopped daptomycin secondary to parotitis for
which no organism was identified but improved when the patient
was changed to vancomycin. No patients experienced myositis or el-
evations in CK levels while on daptomycin. Daptomycin was safe
with no breakthrough gram positive infections and a mean time to
defervescence of 4 days. This pilot study supports future evaluation
